CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis
暂无分享,去创建一个
[1] Jeffrey S. Miller,et al. Human NK Cell Development: One Road or Many? , 2019, Front. Immunol..
[2] R. Hohlfeld,et al. Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation , 2016, Proceedings of the National Academy of Sciences.
[3] T. Yamamura,et al. The regulatory role of natural killer cells in multiple sclerosis. , 2004, Brain : a journal of neurology.
[4] Jeffrey A. Cohen,et al. Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis , 2017, Neurotherapeutics.
[5] M. Mehling,et al. Tissue Distribution Dynamics of Human NK Cells Inferred from Peripheral Blood Depletion Kinetics after Sphingosine‐1‐Phosphate Receptor Blockade , 2015, Scandinavian journal of immunology.
[6] W. Brück,et al. Molecular biomarkers in multiple sclerosis , 2019, Journal of Neuroinflammation.
[7] Antonio Uccelli,et al. Dysregulation of regulatory CD56(bright) NK cells/T cells interactions in multiple sclerosis. , 2016, Journal of autoimmunity.
[8] V. Arolt,et al. Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis , 2016, Neurology: Neuroimmunology & Neuroinflammation.
[9] G. Fink,et al. Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis , 2020, Journal of Neurology.
[10] A. Buriani,et al. Increased NK Cell Count in Multiple Sclerosis Patients Treated With Dimethyl Fumarate: A 2-Year Longitudinal Study , 2019, Front. Immunol..
[11] J. Passweg,et al. CD56bright NK cells after hematopoietic stem cell transplantation are activated mature NK cells that expand in patients with low numbers of T cells , 2010, European journal of immunology.
[12] J. Lechner-Scott,et al. Natural killer cell subpopulations are associated with MRI activity in a relapsing-remitting multiple sclerosis patient cohort from Australia , 2017, Multiple sclerosis.
[13] B. Bielekova,et al. An IL-2 Paradox: Blocking CD25 on T Cells Induces IL-2–Driven Activation of CD56bright NK Cells , 2010, The Journal of Immunology.
[14] A. Barla,et al. New miRNA Signature Heralds Human NK Cell Subsets at Different Maturation Steps: Involvement of miR-146a-5p in the Regulation of KIR Expression , 2018, Front. Immunol..
[15] M. Freedman,et al. The Shifting Landscape of Disease-Modifying Therapies for Relapsing Multiple Sclerosis , 2018, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.
[16] G. Deniz,et al. Dysfunction of CD3-CD16+CD56dim and CD3-CD16-CD56bright NK cell subsets in RR-MS patients. , 2018, Clinical immunology.
[17] Clare Baecher-Allan,et al. Multiple Sclerosis: Mechanisms and Immunotherapy , 2018, Neuron.
[18] R. Schreiber,et al. Type I IFN Contributes to NK Cell Homeostasis, Activation, and Antitumor Function1 , 2007, The Journal of Immunology.
[19] L. Airas,et al. Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta , 2007, Neurological Sciences.
[20] Chuanfeng Wu,et al. Clonal expansion and compartmentalized maintenance of rhesus macaque NK cell subsets , 2018, Science immunology.
[21] T. Waldmann,et al. Intrathecal effects of daclizumab treatment of multiple sclerosis , 2011, Neurology.
[22] Ludwig Kappos,et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. , 2010, The New England journal of medicine.
[23] J. Álvarez-cermeño,et al. Optimal response to dimethyl fumarate associates in MS with a shift from an inflammatory to a tolerogenic blood cell profile , 2018, Multiple sclerosis.
[24] D. Hafler,et al. Regulatory T cells in autoimmune neuroinflammation , 2014, Immunological reviews.
[25] M. Caligiuri,et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. , 2003, Blood.
[26] T. Ghayur,et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. , 2001, Blood.
[27] T. Yamamura,et al. Natural killer type 2 bias in remission of multiple sclerosis. , 2001, The Journal of clinical investigation.
[28] T. Waldmann,et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[29] B. Ursø,et al. Cytotoxicity of CD56bright NK Cells towards Autologous Activated CD4+ T Cells Is Mediated through NKG2D, LFA-1 and TRAIL and Dampened via CD94/NKG2A , 2012, PloS one.
[30] A. Bar-Or,et al. Pre-treatment T-cell subsets associate with fingolimod treatment responsiveness in multiple sclerosis , 2020, Scientific Reports.
[31] M. Mirabella,et al. Circulating CD56dim NK cells expressing perforin are increased in progressive multiple sclerosis , 2013, Journal of Neuroimmunology.
[32] K. Schmierer,et al. Alemtuzumab depletion failure can occur in multiple sclerosis , 2018, Immunology.
[33] M. Sormani,et al. Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis , 2017, Nature Reviews Neurology.
[34] A. Zabalza,et al. Adaptive Features of Natural Killer Cells in Multiple Sclerosis , 2019, Front. Immunol..
[35] J. Sheridan,et al. Intermediate-affinity interleukin-2 receptor expression predicts CD56bright natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis , 2011, Multiple sclerosis.
[36] K. Schmierer,et al. Is it time to target no evident disease activity (NEDA) in multiple sclerosis? , 2015, Multiple sclerosis and related disorders.
[37] H. Wiendl,et al. Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond , 2015, International journal of molecular sciences.
[38] M. Hecker,et al. Transcriptome profiling of peripheral blood immune cell populations in multiple sclerosis patients before and during treatment with a sphingosine‐1‐phosphate receptor modulator , 2018, CNS neuroscience & therapeutics.
[39] J. Buer,et al. Gene and protein characteristics reflect functional diversity of CD56dim and CD56bright NK cells , 2006, Journal of leukocyte biology.
[40] B. Sharrack,et al. Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab , 2019, Neurology: Neuroimmunology & Neuroinflammation.
[41] O. Ciccarelli,et al. Daclizumab-induced encephalitis in multiple sclerosis , 2019, Multiple sclerosis.
[42] A. Maghazachi,et al. Effects of Vitamin D3, Calcipotriol and FTY720 on the Expression of Surface Molecules and Cytolytic Activities of Human Natural Killer Cells and Dendritic Cells , 2013, Toxins.
[43] D. Maric,et al. Unexpected Role for Granzyme K in CD56bright NK Cell-Mediated Immunoregulation of Multiple Sclerosis , 2011, The Journal of Immunology.
[44] Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. , 2012, The New England journal of medicine.
[45] D. Centonze,et al. Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS , 2015, Acta Neuropathologica.
[46] Ludwig Kappos,et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.
[47] A. Laroni. Enhancing natural killer cells is beneficial in multiple sclerosis – Yes , 2018, Multiple sclerosis.
[48] S. Cepok,et al. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS , 2011, Neurology.
[49] G. Foster,et al. Interferon Alpha Induces Sustained Changes in NK Cell Responsiveness to Hepatitis B Viral Load Suppression In Vivo , 2016, PLoS pathogens.
[50] M. Robin,et al. An unusual CD56(bright) CD16(low) NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation. , 2008, Journal of immunology.
[51] A. Thiel,et al. CD56brightCD16− Killer Ig-Like Receptor− NK Cells Display Longer Telomeres and Acquire Features of CD56dim NK Cells upon Activation1 , 2007, The Journal of Immunology.
[52] M. Caligiuri,et al. The biology of human natural killer-cell subsets. , 2001, Trends in immunology.
[53] D. Arnold,et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. , 2012, The New England journal of medicine.
[54] L. Moretta,et al. An Historical Overview: The Discovery of How NK Cells Can Kill Enemies, Recruit Defense Troops, and More , 2019, Front. Immunol..
[55] F. Malavasi,et al. CD56brightCD16− NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4+ T Cell Proliferation , 2015, The Journal of Immunology.
[56] F. Locatelli,et al. Human innate lymphoid cells. , 2016, Immunology letters.
[57] X. Montalban,et al. Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis. , 2011, Clinical immunology.
[58] A. Bar-Or,et al. Reduction of the Peripheral Blood CD56bright NK Lymphocyte Subset in FTY720-Treated Multiple Sclerosis Patients , 2011, The Journal of Immunology.
[59] H. Atkins,et al. Natural Killer Cells Regulate Th17 Cells After Autologous Hematopoietic Stem Cell Transplantation for Relapsing Remitting Multiple Sclerosis , 2018, Front. Immunol..
[60] A. Compston,et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. , 1996, The Journal of clinical investigation.
[61] M. Robin,et al. An Unusual CD56brightCD16low NK Cell Subset Dominates the Early Posttransplant Period following HLA-Matched Hematopoietic Stem Cell Transplantation1 , 2008, The Journal of Immunology.
[62] M. Jordana,et al. Inflammatory monocytes require type I interferon receptor signaling to activate NK cells via IL-18 during a mucosal viral infection , 2017, The Journal of experimental medicine.
[63] F. Al-Shahrour,et al. Immunophenotype and Transcriptome Profile of Patients With Multiple Sclerosis Treated With Fingolimod: Setting Up a Model for Prediction of Response in a 2-Year Translational Study , 2018, Front. Immunol..
[64] D. Bourdette,et al. Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis , 2009, Journal of Neuroimmunology.
[65] M. Caligiuri,et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset , 2001 .
[66] P. Bhargava,et al. Dimethyl fumarate treatment alters NK cell function in multiple sclerosis , 2018, European journal of immunology.
[67] B. Engelhardt,et al. T‐cell trafficking in the central nervous system , 2012, Immunological reviews.
[68] G. Comi,et al. Evolving concepts in the treatment of relapsing multiple sclerosis , 2017, The Lancet.
[69] H. Weiner,et al. IL-27 Imparts Immunoregulatory Function to Human NK Cell Subsets , 2011, PloS one.
[70] Dimethyl fumarate induces a persistent change in the composition of the innate and adaptive immune system in multiple sclerosis patients , 2018, Scientific Reports.
[71] H. Wiendl,et al. Regulatory Functions of Natural Killer Cells in Multiple Sclerosis , 2016, Front. Immunol..
[72] M. Schilham,et al. Expansion of cytotoxic CD56bright natural killer cells during T-cell deficiency after allogeneic hematopoietic stem cell transplantation. , 2017, The Journal of allergy and clinical immunology.